119 related articles for article (PubMed ID: 35114211)
1. Immunochemical and biophysical characterization of inactivated Sabin poliovirus products: Insights into rapid quality assessment tools.
Westdijk J; Kogelman A; van der Put R; Eksteen Z; Suarez D; Kersten GFA; Metz B; Danial M
J Pharm Sci; 2022 Apr; 111(4):1058-1069. PubMed ID: 35114211
[TBL] [Abstract][Full Text] [Related]
2. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
[TBL] [Abstract][Full Text] [Related]
3. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba.
Resik S; Tejeda A; Fonseca M; Alemañi N; Diaz M; Martinez Y; Garcia G; Okayasu H; Burton A; Bakker WA; Verdijk P; Sutter RW
Vaccine; 2014 Sep; 32(42):5399-404. PubMed ID: 25131734
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
Hotta C; Ogawa T; Shirasawa H
Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
[TBL] [Abstract][Full Text] [Related]
5. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
Kersten G; Hazendonk T; Beuvery C
Vaccine; 1999 Apr; 17(15-16):2059-66. PubMed ID: 10217607
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X
Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement.
Chen H; Gao Z; Bai S; Liu X; Han S; Xiao Y; Liu F; Yu Y; Sun H; Yang X
Vaccine; 2021 Apr; 39(17):2467-2474. PubMed ID: 33810904
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
[TBL] [Abstract][Full Text] [Related]
9. Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses.
Sun M; Li C; Xu W; Liao G; Li R; Zhou J; Li Y; Cai W; Yan D; Che Y; Ying Z; Wang J; Yang H; Ma Y; Ma L; Ji G; Shi L; Jiang S; Li Q
Clin Infect Dis; 2017 May; 64(10):1317-1325. PubMed ID: 28419204
[TBL] [Abstract][Full Text] [Related]
10. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.
Taniuchi M; Famulare M; Zaman K; Uddin MJ; Upfill-Brown AM; Ahmed T; Saha P; Haque R; Bandyopadhyay AS; Modlin JF; Platts-Mills JA; Houpt ER; Yunus M; Petri WA
Lancet Infect Dis; 2017 Oct; 17(10):1069-1079. PubMed ID: 28693854
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical Characterization of Sabin Inactivated Poliovirus Vaccine for Process Development.
Torisu T; Shikama S; Nakamura K; Enomoto K; Maruno T; Mori A; Uchiyama S; Satou T
J Pharm Sci; 2021 May; 110(5):2121-2129. PubMed ID: 33340531
[TBL] [Abstract][Full Text] [Related]
12. Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany.
Eggers M; Terletskaia-Ladwig E; Rabenau HF; Doerr HW; Diedrich S; Enders G; Enders M
BMC Infect Dis; 2010 Dec; 10():347. PubMed ID: 21143885
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.
Verdijk P; Rots NY; Bakker WA
Expert Rev Vaccines; 2011 May; 10(5):635-44. PubMed ID: 21604984
[TBL] [Abstract][Full Text] [Related]
14. Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine.
Liao G; Li R; Li C; Sun M; Jiang S; Li Y; Mo Z; Xia J; Xie Z; Che Y; Yang J; Yin Z; Wang J; Chu J; Cai W; Zhou J; Wang J; Li Q
J Infect Dis; 2016 Dec; 214(11):1728-1734. PubMed ID: 27658691
[TBL] [Abstract][Full Text] [Related]
15. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.
Shimizu H
Vaccine; 2016 Apr; 34(16):1975-85. PubMed ID: 25448090
[TBL] [Abstract][Full Text] [Related]
16. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
Bakker WA; Thomassen YE; van't Oever AG; Westdijk J; van Oijen MG; Sundermann LC; van't Veld P; Sleeman E; van Nimwegen FW; Hamidi A; Kersten GF; van den Heuvel N; Hendriks JT; van der Pol LA
Vaccine; 2011 Sep; 29(41):7188-96. PubMed ID: 21651934
[TBL] [Abstract][Full Text] [Related]
17. Sporadic isolation of sabin-like polioviruses and high-level detection of non-polio enteroviruses during sewage surveillance in seven Italian cities, after several years of inactivated poliovirus vaccination.
Battistone A; Buttinelli G; Fiore S; Amato C; Bonomo P; Patti AM; Vulcano A; Barbi M; Binda S; Pellegrinelli L; Tanzi ML; Affanni P; Castiglia P; Germinario C; Mercurio P; Cicala A; Triassi M; Pennino F; Fiore L
Appl Environ Microbiol; 2014 Aug; 80(15):4491-501. PubMed ID: 24814793
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants.
Verdijk P; Rots NY; van Oijen MG; Weldon WC; Oberste MS; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2014 Sep; 32(39):4938-44. PubMed ID: 25043278
[TBL] [Abstract][Full Text] [Related]
19. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
Sanders BP; Oakes Ide L; van Hoek V; Liu Y; Marissen W; Minor PD; Wimmer E; Schuitemaker H; Custers JH; Macadam A; Cello J; Edo-Matas D
Vaccine; 2015 Nov; 33(48):6611-6. PubMed ID: 26529068
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.
Liao G; Li R; Li C; Sun M; Li Y; Chu J; Jiang S; Li Q
J Infect Dis; 2012 Jan; 205(2):237-43. PubMed ID: 22158682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
